GLP-1 vs Retatrutide for Fat Loss: Which Wins?

By Victor Björk

The Verdict Up Front

Retatrutide produces more weight loss than any approved GLP-1 monotherapy agent, based on the evidence currently available. A 2025 meta-analysis of three retatrutide RCTs in 878 adults with obesity found mean body weight reductions of 14.33% compared to placebo across dose groups, and the 12 mg arm of the Phase 2 obesity trial reached 24.2% at 48 weeks. [1] Semaglutide 2.4 mg, the most studied GLP-1 receptor agonist for obesity, achieved approximately 14.9% over 68 weeks in STEP 1. [2] The magnitude difference is real, not a rounding artifact.

The catch is obvious: retatrutide is not approved anywhere. You can enroll in a Phase 3 trial or, depending on jurisdiction, obtain it through a compounding pharmacy with no regulatory assurance of purity or potency. For most clinicians managing patients today, that limits the practical relevance of the efficacy advantage considerably.

What Each Compound Does

GLP-1 receptor agonists like semaglutide and liraglutide mimic endogenous glucagon-like peptide-1, slowing gastric emptying, suppressing glucagon secretion, and reducing appetite through hypothalamic GLP-1 receptors. [3] The weight loss mechanism is primarily intake reduction. Energy expenditure effects at therapeutic doses are modest and inconsistent across studies.

Retatrutide adds two more receptor targets. It is a triple agonist at GLP-1, GIP, and glucagon receptors simultaneously, and the glucagon receptor component is where the mechanistic story gets more interesting. A 2024 Cell review of multi-receptor obesity drugs noted that GLP-1-based polyagonists incorporating glucagon receptor activity achieve complementary pharmacology, with favorable effects on fatty liver and adipose tissue, reaching weight reductions of up to 20-30% in trials. [4] The GIP component, as seen with tirzepatide, appears to enhance GLP-1 receptor signaling and improve tolerability at equivalent GLP-1 receptor stimulation. The glucagon component adds direct thermogenic activity and hepatic fat mobilization beyond what GLP-1 or GLP-1/GIP agonism alone provides.

On the energy expenditure question specifically: a 2025 systematic review of GLP-1 receptor agonist effects on mitochondrial function found that GLP-1 RAs appear to increase mitochondrial area and number in skeletal muscle in animal and in-vitro studies, but effects on mitochondrial respiration and uncoupling proteins remain inconclusive, with no human studies identified. [5] The preclinical thermogenic signal from glucagon receptor agonism is plausible, but calling it established in humans overstates what the trial data show.

Head-to-Head: Efficacy for Fat Loss

The 2025 meta-analysis pooling three retatrutide RCTs (878 participants) found mean weight reductions of 14.33% versus placebo, along with significant reductions in BMI, waist circumference, blood pressure, fasting glucose, and HbA1c. [1] The 12 mg dose arm of the Phase 2 obesity trial specifically reached 24.2% at 48 weeks, a number not reported for any approved GLP-1 monotherapy over a comparable trial duration. [1]

Tirzepatide, the dual GLP-1/GIP agonist approved for obesity, achieved 20.9% at 72 weeks at the 15 mg dose in SURMOUNT-1. A meta-analysis of 10 tirzepatide RCTs across 9,873 participants confirmed significant weight reduction versus placebo and versus GLP-1 monotherapy across all three doses. [6] Tirzepatide sits between semaglutide and retatrutide on the efficacy ladder, which makes mechanistic sense given it adds GIP but not glucagon receptor activity.

There is no published head-to-head RCT comparing retatrutide directly to semaglutide or any other GLP-1 agonist on a weight-loss endpoint as of mid-2025. Every comparison here is cross-trial, meaning different populations, different titration schedules, different dropout handling, and different trial durations. The point estimates favor retatrutide, but the confidence intervals around cross-trial comparisons are wide and the confounds are real.

The evidentiary base for retatrutide also remains thin relative to what exists for semaglutide and tirzepatide. The Phase 1b trial that established retatrutide’s early safety and pharmacokinetics enrolled 72 participants with type 2 diabetes over 12 weeks. [7] Phase 3 trials are ongoing. The efficacy signal from Phase 2 is striking, but a single Phase 2 study with a few hundred participants is not the same foundation as the multi-trial programs behind the approved agents.

Head-to-Head: Safety

The 2025 meta-analysis of retatrutide RCTs found no statistically significant difference in overall adverse events between retatrutide and placebo (RR: 1.11, p=0.24), though nausea, vomiting, and diarrhea followed the dose-dependent pattern expected from GLP-1 receptor agonism. [1] The authors noted the need for larger long-term trials before drawing firm conclusions about safety.

Semaglutide’s cardiovascular safety profile is substantially better characterized. The SELECT trial, a prespecified analysis of which was published in 2025, found that semaglutide’s cardioprotective effects were independent of baseline adiposity and that only about a third of the MACE benefit was mediated through waist circumference reduction, suggesting mechanisms beyond weight loss alone. [8] That kind of outcomes data simply does not exist for retatrutide yet, and the absence matters clinically.

The glucagon receptor component in retatrutide raises questions that have not been resolved in humans. A 2021 review of proglucagon-derived peptides noted that dual and triple agonists incorporating glucagon receptor activity are in development, but concerns around heart rate elevation and hepatic glucose output effects from glucagon agonism in long-term human use remain open. [9] This is not a reason to dismiss the compound, but it is a reason not to assume the safety profile mirrors semaglutide’s.

On thyroid risk: a 2025 narrative review of GLP-1 receptor agonists noted that early concerns about thyroid C-cell tumors, which are based on rodent data and carry an FDA boxed warning for the class, have been largely attenuated by more recent evidence, though ongoing investigation remains warranted. [10] Because retatrutide activates GLP-1 receptors, the class warning applies by mechanism, even though human causation has not been established for any agent in the class.

Head-to-Head: Practical Considerations

Both semaglutide and retatrutide are administered as once-weekly subcutaneous injections, so dosing frequency is equivalent. [11] The titration schedules differ, but the injection burden is the same.

Cost and access diverge sharply. Semaglutide 2.4 mg (Wegovy) carries a high list price in the United States, and while compounded semaglutide has been available at lower cost during shortage periods, direct pricing information was not confirmed in the reviewed literature, so specific figures are omitted here. Semaglutide is commercially available, insurance-reimbursable in many plans, and prescribed through standard clinical channels.

Retatrutide is not commercially available as of mid-2025. Clinical trial enrollment is the regulated path. Compounding pharmacy access exists in some jurisdictions but carries no regulatory assurance of purity, potency, or sterility. For a clinician trying to manage a patient’s obesity today, this is a meaningful practical constraint regardless of the efficacy data.

The Scenarios Where Each Wins

For patients with type 2 diabetes and obesity who need an approved, potentially insurance-reimbursable agent with established cardiovascular outcome data, semaglutide or tirzepatide are the appropriate first-line choices. The regulatory and safety infrastructure simply isn’t in place for retatrutide to compete on those terms yet.

The population where retatrutide’s mechanistic rationale is most compelling is patients who have plateaued on GLP-1 monotherapy and are willing to accept the uncertainty of a Phase 3-stage compound. The additional glucagon receptor activity offers a pathway to greater weight reduction that GLP-1 alone cannot provide, and the Phase 2 magnitude data support that reasoning even if Phase 3 confirmation is pending.

A Phase 2a trial in participants with metabolic dysfunction-associated steatotic liver disease found retatrutide produced mean relative liver fat reductions of up to approximately 82% at 24 weeks, with liver fat reductions significantly correlated with body weight changes. [11] The hepatic fat-mobilizing effect from glucagon receptor agonism may give retatrutide particular utility in severe obesity with significant metabolic comorbidity, a population where GLP-1 monotherapy has historically underperformed.

Bottom Line

Retatrutide’s Phase 2 efficacy signal is the largest reported for any injectable obesity agent in trials to date. The 24.2% mean weight loss at 48 weeks in the high-dose group, and the 14.33% pooled reduction across dose groups in the meta-analysis, are numbers that semaglutide and tirzepatide do not match at comparable timepoints. [1]

One Phase 2 program is not the same evidentiary foundation as the multi-trial Phase 3 packages that got semaglutide and tirzepatide approved. Until Phase 3 data land and a regulatory agency reviews the full safety dataset, retatrutide’s efficacy advantage cannot be cleanly separated from the possibility of dose optimization effects, population selection, or safety signals that only emerge at scale. The glucagon receptor activity that makes retatrutide mechanistically interesting is also the least characterized component in long-term human use — and that gap will matter more, not less, as the doses being studied in Phase 3 push toward the high end of what Phase 2 tested.

This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.

References

1. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials.. Proceedings (Baylor University. Medical Center), 2025.

2. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists.. Frontiers in endocrinology, 2024.

3. Glucagon-like peptide agonists: A prospective review.. Endocrinology, diabetes & metabolism, 2024.

4. Transforming obesity: The advancement of multi-receptor drugs.. Cell, 2024.

5. The Effects of Glucagon-Like Peptide-1 Receptor Agonists on Mitochondrial Function Within Skeletal Muscle: A Systematic Review.. Journal of cachexia, sarcopenia and muscle, 2025.

6. Weight loss efficiency and safety of tirzepatide: A Systematic review.. PloS one, 2023.

7. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.. Lancet (London, England), 2022.

8. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial.. Lancet (London, England), 2025.

9. Proglucagon-Derived Peptides as Therapeutics.. Frontiers in endocrinology, 2021.

10. The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions.. EClinicalMedicine, 2025.

11. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.. Nature medicine, 2024.